# Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

> **NCT03242967** · PHASE3 · WITHDRAWN · sponsor: **Akebia Therapeutics**

## Conditions studied

- Anemia
- Dialysis-Dependent Chronic Kidney Disease

## Interventions

- **DRUG:** Vadadustat
- **DRUG:** Darbepoetin alfa

## Key facts

- **NCT ID:** NCT03242967
- **Lead sponsor:** Akebia Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-08
- **Primary completion:** 2018-02-12
- **Final completion:** 2018-02-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Revised study design.
- **Last updated:** 2018-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03242967

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03242967, "Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03242967. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*